Preview Mode Links will not work in preview mode

Thank you for listening in. We appreciate feedback and are always looking for suitable guests. 

Nov 15, 2019

Roughly 3.5 million Americans are being prescribed or using medical cannabis today. But, how can a person or a medical provider know that what they are using, or prescribing, is the most effective strain for their, or their patient's, treatment plan?

In this episode of Hilary Topper On Air, Hilary interviews Stephanie Karasick, Co-Founder & Chief Creative Officer of Strainprint Technologies Ltd., the leading demand-side cannabis data and analytics company.

About Stephanie

Stephanie was born and raised in the suburbs of Montreal, and left shortly after getting her degree in Graphic Design. She moved to Toronto, working as a copywriter at Leo Burnett, Saatchi & Saatchi, JWT, Taxi, and MacLaren McCann over a span of 15 years. Somewhere in that time, she began studying photography. She also left the corporate world to work as an editorial and family photographer and a mom. The idea for Strainprint came to her after her first few months of using medical cannabis. She was noticing how little information and scientific validation there was on various treatments. Watch Steph's Video

About the Interview

Stephanie will discuss:

  • The genesis of Strainprint and her story
  • Why the medical cannabis app is important for individuals
  • The importance of medical cannabis data
  • What their data is telling us and why that is important
  • Why continuing to break the stigma of medical cannabis and legitimizing it as a viable therapeutic option is important

About Strainprint™

Founded in Toronto in 2016, StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company. With the world's largest longitudinal, observational dataset of its kind and a mission to advance the scientific understanding of cannabis and its legitimization as a mainstream therapy, Strainprint helps medical cannabis patients and doctors to use cannabis in the most effective and responsible way possible. Strainprint's data platform supports global cannabis research and provides advanced business intelligence and treatment guidance to producers, retailers, medical practitioners, pharmacies, government, and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted, and all patient data is completely anonymized and at rest in Canada. It can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. Strainprint Analytics is accessed by customer subscriptions. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and Google Play Store. www.strainprint.ca, Facebook, Twitter, LinkedIn. Strainprint Reports are available at https://strainprint.ca/strainprint-reports/.